3D DENTAL DESIGNS AND DEVELOPMENT, LLC GT-2 Visionary by 3D Dental

Amplatz Type Renal Dilator/Sheath Set

Linet Birthing Bed with Accessories1420748

These Stryker 3002 Ex Secure 2 Beds are in fully functional condition and include electric controls for adjusting the head, foot, and height positions, along with Trendelenburg capabilities. The bed has adjustable side rails and a secure braking system. It also features pressure-relief surfaces.

Standalone software as medical device (SaMD) designed to automatically analyse within seconds magnetic resonance imaging (MRI) datasets to generate an estimate of the patient’s volumetric liver fat fraction (VLFF), converted into proton density fat fraction (PDFF) and steatosis grade. No user input is required for the analysis thus minimising the impact of human error on obtained results. HepaFatSmart is intended for the quantitative evaluation of volumetric liver fat fraction (VLFF), proton density fat fraction (PDFF) and liver steatosis grading.It utilises magnetic resonance images that exploit the difference in resonance frequencies between hydrogen nuclei in water and triglyceride fat. The quantitative triglyceride fat fraction is based on the measurement of a magnetic resonance parameter that reflects the ratio of the proton density signal of triglyceride fat to the total proton density signal in the liver.When interpreted by a trained physician, the results provide information that can aid in diagnosis.HepaFatSmart is indicated to:• Support clinical diagnoses in individuals with confirmed or suspected fatty liver disease; • Assessment of liver fat content to support the subsequent clinical decision-making processes for patients under management of diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), viral hepatitis. • Support the subsequent clinical decision-making processes for patients Results, when interpreted by a trained physician can be used to support clinical diagnoses about the status of liver fat content, the subsequent clinical decision-making processes for the management of fatty liver related diseases.

BIO-COMP CRKSCRW FT VENTD 5.5X14.7MM

SUTR ANCH,CRKSCRW

SCREW, CANN. INT., FULL THREAD

SCRW,CANN. INT.,W/DISP SHTH

TIGHTROPE ABS, BUTTON, 8 X 12 MM

Looking to sell brand new Endoscope Guide devices by Olympus. They were purchased in 04/2018 for $17,900 and never opened. ScopeGuide UPD-3 is an exclusive Olympus technology designed to provide a real-time 3D image of the shape and position of the endoscope inside the body.

Amplatz Type Renal Dilator/Sheath Set

Linet Birthing Bed with Accessories1420748

These Stryker 3002 Ex Secure 2 Beds are in fully functional condition and include electric controls for adjusting the head, foot, and height positions, along with Trendelenburg capabilities. The bed has adjustable side rails and a secure braking system. It also features pressure-relief surfaces.

Standalone software as medical device (SaMD) designed to automatically analyse within seconds magnetic resonance imaging (MRI) datasets to generate an estimate of the patient’s volumetric liver fat fraction (VLFF), converted into proton density fat fraction (PDFF) and steatosis grade. No user input is required for the analysis thus minimising the impact of human error on obtained results. HepaFatSmart is intended for the quantitative evaluation of volumetric liver fat fraction (VLFF), proton density fat fraction (PDFF) and liver steatosis grading.It utilises magnetic resonance images that exploit the difference in resonance frequencies between hydrogen nuclei in water and triglyceride fat. The quantitative triglyceride fat fraction is based on the measurement of a magnetic resonance parameter that reflects the ratio of the proton density signal of triglyceride fat to the total proton density signal in the liver.When interpreted by a trained physician, the results provide information that can aid in diagnosis.HepaFatSmart is indicated to:• Support clinical diagnoses in individuals with confirmed or suspected fatty liver disease; • Assessment of liver fat content to support the subsequent clinical decision-making processes for patients under management of diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), viral hepatitis. • Support the subsequent clinical decision-making processes for patients Results, when interpreted by a trained physician can be used to support clinical diagnoses about the status of liver fat content, the subsequent clinical decision-making processes for the management of fatty liver related diseases.